PHAT Quote, Financials, Valuation and Earnings

NovaBay Pharmaceuticals has a net margin of -330.71% compared to Phathom Pharmaceuticals's net margin of -49.65%. Phathom Pharmaceuticals's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Phathom Pharmaceuticals has a consensus price target of $19.88, signalling upside risk potential of 138.6%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 31.62%. Given that Phathom Pharmaceuticals has higher upside potential than NovaBay Pharmaceuticals, analysts believe Phathom Pharmaceuticals is more attractive than NovaBay Pharmaceuticals.

Phathom Pharmaceuticals has a beta of 0.453, which suggesting that the stock is 54.724% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.443, suggesting its less volatile than the S&P 500 by 55.681%.

Phathom Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Phathom Pharmaceuticals pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Phathom Pharmaceuticals quarterly revenues are $28.5M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Phathom Pharmaceuticals's net income of -$94.3M is lower than NovaBay Pharmaceuticals's net income of $7.7M. Notably, Phathom Pharmaceuticals's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Phathom Pharmaceuticals is 6.77x versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Oragenics has a net margin of -330.71% compared to Phathom Pharmaceuticals's net margin of --. Phathom Pharmaceuticals's return on equity of -- beat Oragenics's return on equity of --.

Phathom Pharmaceuticals has a consensus price target of $19.88, signalling upside risk potential of 138.6%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 2012.89%. Given that Oragenics has higher upside potential than Phathom Pharmaceuticals, analysts believe Oragenics is more attractive than Phathom Pharmaceuticals.

Phathom Pharmaceuticals has a beta of 0.453, which suggesting that the stock is 54.724% less volatile than S&P 500. In comparison Oragenics has a beta of 0.946, suggesting its less volatile than the S&P 500 by 5.446%.

Phathom Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Phathom Pharmaceuticals pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.

Phathom Pharmaceuticals quarterly revenues are $28.5M, which are larger than Oragenics quarterly revenues of --. Phathom Pharmaceuticals's net income of -$94.3M is lower than Oragenics's net income of -$2.2M. Notably, Phathom Pharmaceuticals's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Phathom Pharmaceuticals is 6.77x versus 0.45x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.

Sage Therapeutics has a net margin of -330.71% compared to Phathom Pharmaceuticals's net margin of -442.4%. Phathom Pharmaceuticals's return on equity of -- beat Sage Therapeutics's return on equity of -64.19%.

Phathom Pharmaceuticals has a consensus price target of $19.88, signalling upside risk potential of 138.6%. On the other hand Sage Therapeutics has an analysts' consensus of $8.73 which suggests that it could fall by -4.4%. Given that Phathom Pharmaceuticals has higher upside potential than Sage Therapeutics, analysts believe Phathom Pharmaceuticals is more attractive than Sage Therapeutics.

Phathom Pharmaceuticals has a beta of 0.453, which suggesting that the stock is 54.724% less volatile than S&P 500. In comparison Sage Therapeutics has a beta of 0.294, suggesting its less volatile than the S&P 500 by 70.557%.

Phathom Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sage Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Phathom Pharmaceuticals pays -- of its earnings as a dividend. Sage Therapeutics pays out -- of its earnings as a dividend.

Phathom Pharmaceuticals quarterly revenues are $28.5M, which are larger than Sage Therapeutics quarterly revenues of $14.1M. Phathom Pharmaceuticals's net income of -$94.3M is lower than Sage Therapeutics's net income of -$62.2M. Notably, Phathom Pharmaceuticals's price-to-earnings ratio is -- while Sage Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Phathom Pharmaceuticals is 6.77x versus 11.79x for Sage Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of -330.71% compared to Phathom Pharmaceuticals's net margin of --. Phathom Pharmaceuticals's return on equity of -- beat Theriva Biologics's return on equity of --.

Phathom Pharmaceuticals has a consensus price target of $19.88, signalling upside risk potential of 138.6%. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1402.15%. Given that Theriva Biologics has higher upside potential than Phathom Pharmaceuticals, analysts believe Theriva Biologics is more attractive than Phathom Pharmaceuticals.

Phathom Pharmaceuticals has a beta of 0.453, which suggesting that the stock is 54.724% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 0.816, suggesting its less volatile than the S&P 500 by 18.373%.

Phathom Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Phathom Pharmaceuticals pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

Phathom Pharmaceuticals quarterly revenues are $28.5M, which are larger than Theriva Biologics quarterly revenues of --. Phathom Pharmaceuticals's net income of -$94.3M is lower than Theriva Biologics's net income of -$4.3M. Notably, Phathom Pharmaceuticals's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Phathom Pharmaceuticals is 6.77x versus 0.33x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.